Asthma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Advertisements

DelveInsight’s, “Asthma Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including Asthma clinical trials and nonclinical stage products. It also covers the Asthma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Asthma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Asthma NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Key takeaways from Asthma Pipeline Insight Report

 

DelveInsight’s Asthma Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Asthma.
The leading Asthma Companies such as Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others are developing therapies for the Asthma treatment.
Promising Asthma Pipeline therapies such as A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others.
The Asthma companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The Asthma pipeline therapies under development are focused on novel approaches to treat/improve Asthma.

 

To explore more information on the latest breakthroughs in the Asthma Pipeline treatment landscape of the report, click here @ Asthma Pipeline Outlook

 

Asthma Overview

Asthma is a chronic disease that affects the airways.  Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness. Symptoms of asthma vary from person to person. A person may have infrequent asthma attacks or have symptoms only at a certain time such as when exercising or may have symptoms all the time. Symptoms of asthma resemble many respiratory infections. The first step in asthma diagnosis is a careful clinical history; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on the quality of life.

 

Recent Breakthroughs of Asthma Treatment Landscape

 

In October 2021, The board of directors of Mabpharm Limited announced that the new drug application (NDA) of CMAB007 (omalizumab), a core product of the Company, was accepted by the National Medical Products Administration of the People’s Republic of China (“NMPA”) for the treatment of allergic asthma, which is the first domestic allergic asthma therapeutic antibody new drug in China with NDA submitted. CMAB007 (omalizumab) is the second drug to be submitted for marketing application by the Company.
In September 2021, Evelo Biosciences, Inc. announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medicines comprising pharmaceutical compositions of Veillonella parvula bacteria. This patent is a key addition to the Company’s substantial and growing intellectual property (IP) portfolio for treatments targeting the small intestinal axis, SINTAX™.
In November 2021, CSPC Pharmaceutical Group Limited (the “Company” announced that Shanghai JMT-BIO Technology Co., Ltd, a wholly-owned subsidiary of the Company, has entered into an agreement (the “Agreement”) with Keymed Bioscience (Chengdu) Co., Ltd. in relation to the exclusive licensing and commercialization of the product CM326 (an anti-TSLP recombinant humanized monoclonal antibody, the “Product”) in the treatment of moderate to severe asthma, chronic obstructive pulmonary disease (COPD) and other respiratory system diseases.
In November 2021, Amgen and AstraZeneca agreed to include AMG 104 / AZD8630 in the existing collaboration agreement between the parties. AMG 104 / AZD8630 becomes part of the collaboration with the companies sharing both costs and income, with no inventor royalty.

 

Asthma Emerging Drugs Profile

 

PT-027: Avillion LLP

PT027 is an investigational fixed dose combination of budesonide (an inhaled corticosteroid) and albuterol (a short-acting beta-2 agonist). It is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed in response to symptoms. It is an inhaled, fixed-dose combination of albuterol (also known as salbutamol), a SABA, and budesonide, a corticosteroid, and is being developed in a pMDI using AstraZeneca’s Aerosphere delivery technology. Avillion will be responsible for developing PT027 through an extensive clinical development programme and will finance the programme through to regulatory approval.

 

MM09-MG01: Inmunotek S.L.

It is a mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde. It is currently being developed in Phase III stage of development.

 

FP 025: Foresee Pharmaceuticals

Foresee is developing a new generation, novel oral, highly selective and potent non-hydroxamate class of matrix metalloproteinase-12 (MMP-12) inhibitors for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and multiple other diseases by rational drug design. A lead compound, FP-025, has been investigated in Phase I human clinical trials and proved to show acceptable safety and tolerability, and stable pharmacokinetics in healthy subjects. A Phase II proof-of-concept study in allergic asthma patients is currently being conducted in the Netherlands.

 

GB001: Gossamer Bio

GB001, a DP2 antagonist, may inhibit recruitment and activation of inflammatory cells in patients with asthma, consequently reducing airway inflammation. DP2 is a G-protein-coupled receptor selectively expressed by Type 2 T lymphocytes (Th2), eosinophils (Eos), basophils and Type 2 innate lymphoid cells (ILC2s). DP2 binds to PGD2 and promotes recruitment and activation of eosinophils and basophils and stimulates Th2 cells and ILC2 cells to release Type 2 cytokines including IL-4, IL-5 and IL-13, leading to persistence of Type 2 inflammation.GB001 is a potent and highly selective oral DP2 antagonist being developed as a once daily oral add-on maintenance treatment for moderate to severe eosinophilic asthma. In preclinical studies, GB001 was shown to be an insurmountable antagonist with a prolonged effect.

 

EDP1867: Evelo Biosciences, Inc.

EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor. It is made non-live by γ-irradiation in the manufacturing process making it unable to colonize or persist in the gut, a central feature of SINTAX medicines. EDP1867 is currently in clinical development. It has the potential to treat a wide range of inflammatory and neuroinflammatory diseases.

 

TQC2731: Chia Tai Tianqing Pharmaceutical Group

TQC2731, belongs to the class of antiasthmatics. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in your airways. An antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm.TQC2731 is currently being investigated in Phase1 for the treatment of Asthma.

 

Asthma Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Avillion LLP.

 

Scope of the Asthma Pipeline Report

Coverage- Global
Asthma Companies- Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others
Asthma Therapies- A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others.
Asthma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Table of content

Introduction
Asthma Executive Summary
Asthma: Overview
Asthma Pipeline Therapeutics
Asthma Pipeline Therapeutic Assessment
Asthma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
PT-027: Avillion LLP
Mid Stage Products (Phase II/III)
PT001: Pearl Therapeutics (AstraZeneca)
Mid Stage Products (Phase II)
FP 025: Foresee Pharmaceuticals
Early Stage Products (Phase I/II)
AQ-001S: Aquilon Pharmaceuticals S.A
Early Stage Products (Phase I)
Itolizumab (EQ001): Equillium
Preclinical and Discovery Stage Products
KBP7026: KBP Biosciences
Inactive Products
Asthma Key Companies
Asthma Key Products
Asthma- Unmet Needs
Asthma- Market Drivers and Barriers
Asthma- Future Perspectives and Conclusion
Asthma Analyst Views
Asthma Key Companies
Appendix

 

Got Queries? Find out the related information on Asthma Mergers and acquisitions, Asthma Licensing Activities @ Asthma Emerging Drugs, and Recent Trends

 

Trending Reports- Stem Cell Market | Asperger Syndrome Market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.

Advertisements

Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: